Skip to contentB
Bristol Myers Squibb Co
B
BMYBristol Myers Squibb Co Q2 2026 · 10-Q
Revenue$12.97B$12.97B+5.7% vs Q2 2025 Net Income$3.32B$3.32B+153.2% vs Q2 2025 EPS Diluted$1.62$1.62+153.1% vs Q2 2025 Operating Cash Flowderived$3,393,000,000−13.4% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bristol Myers Squibb Co · CIK 14272 · Engraved from SEC EDGAR
Free Cash Flowderived$3,088,000,000−13.2% Margins · derivedNet margin25.6%+14.9 pt vs Q2 2025
ended Jun 30, 2026 · filed Jul 30, 2026 · 30 d after period end